6/28/23, 12:51 AM Age Trial Pathway Feedback Search Clinical Topics Home Studies Age Trial Age Trial Trial question What is the role of mammographic screening on breast cancer mortality in women aged 39-41 years? Study design Multi-center Open label RCT Population 160921 female patients Inclusion criteria: women aged 39-41 years Key exclusion criteria: men, not traceable at NHSCR, deceased before entry, or emigrated before entry Interventions N=53884 intervention (annual mammography to age 48 years) N=106956 control (usual medical care) Primary outcome Rate of breast-cancer death at a mean follow-up of 10.7 years 2.2 % 2.2 1.8 1.7 % 1.1 % 0.6 % No significant difference 0.0 % Intervention Control No significant difference in the rate of breast-cancer death at a mean follow-up of 10.7 years (1.8% vs. 2.2%; RR 0.83, 95% CI 0.66 to 1.04) Secondary outcomes https://web.pathway.md/studies/recAWgxjNOCML1sSX 1/2 6/28/23, 12:51 AM Age Trial Pathway No significant difference in death from all causes (16.6% vs. 17.2%; RR 0.97, 95% CI 0.89 to 1.04) No significant difference in the rate of breast-cancer death from 0-5 years (1% vs. 1.2%; RR 0.79, 95% CI 0.48 to 1.27) No significant difference in the rate of breast-cancer death from 5-15 years (2.5% vs. 3%; RR 0.84, 95% CI 0.64 to 1.1) Conclusion In women aged 39-41 years, intervention was not superior to control with respect to the rate of breast-cancer death at a mean follow-up of 10.7 years. Reference Moss SM, Cuckle H, Evans A et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet. 2006 Dec 9;368(9552):2053-60. Open reference URL https://web.pathway.md/studies/recAWgxjNOCML1sSX 2/2